Paul Tudor Jones’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.7M Buy
197,331
+126,542
+179% +$4.09M 0.01% 988
2026
Q1
$2.3M Buy
70,789
+22,180
+46% +$713K ﹤0.01% 1750
2025
Q4
$1.71M Buy
+48,609
New +$1.72M ﹤0.01% 1917
2025
Q2
Sell
-172,124
Closed -$4.53M 3797
2025
Q1
$4.16M Buy
+172,124
New +$5.44M 0.01% 877
2023
Q3
Sell
-41,544
Closed -$673K 2911
2023
Q2
$673K Buy
41,544
+13,652
+49% +$286K 0.01% 1545
2023
Q1
$464K Buy
27,892
+13,000
+87% +$134K 0.01% 1655
2022
Q4
$140K Buy
+14,892
New +$66.5K ﹤0.01% 2186

Other funds holding VKTX

Paul Tudor Jones's VKTX Position: Q2 2026 in Review

Paul Tudor Jones increased its Viking Therapeutics (VKTX) stake by 179% in Q2 2026, buying an estimated $4.09M and bringing the position to 197,331 shares worth $7.7M. The position accounts for 0.01% of the portfolio, ranked #988.

Paul Tudor Jones first reported a position in VKTX in Q4 2022 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Paul Tudor Jones held 197,331 shares of Viking Therapeutics worth $7.7M as of Q2 2026.
  • Paul Tudor Jones bought 126,542 Viking Therapeutics shares in Q2 2026, an estimated $4.09M.
  • Viking Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #988 holding.
  • Paul Tudor Jones first reported a position in Viking Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.